STOCK TITAN

Polypid Ltd - PYPD STOCK NEWS

Welcome to our dedicated news page for Polypid (Ticker: PYPD), a resource for investors and traders seeking the latest updates and insights on Polypid.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Polypid's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Polypid's position in the market.

Rhea-AI Summary
PolyPid announces positive preclinical results demonstrating the safety profile of D-PLEX100 and the PLEX technology platform in juvenile animals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
clinical trial
-
Rhea-AI Summary
PolyPid to present at Cantor Global Healthcare Conference on September 28, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.24%
Tags
conferences
-
Rhea-AI Summary
PolyPid successfully completes audit of manufacturing facility for D-PLEX100, bringing them closer to global commercialization
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.74%
Tags
none
News
Rhea-AI Summary
PolyPid announces reverse share split at ratio of 1-for-30 to improve surgical outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3558.21%
Tags
none
-
Rhea-AI Summary
PolyPid successfully completes production of three process validation batches of D-PLEX100, a substantial requirement for regulatory filings. Capacity expansion triples manufacturing capacity for global markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.87%
Tags
none
-
Rhea-AI Summary
PolyPid Ltd. (Nasdaq: PYPD) reached an agreement with the U.S. FDA on the design of the SHIELD II Phase 3 trial evaluating D-PLEX100 for the prevention of abdominal colorectal surgical site infections. The company resumed recruitment into the SHIELD II Phase 3 trial in late June 2023, with a total of 20 centers in the U.S., Europe, and Israel expected to be opened by the end of the current quarter. They also reported financial results for the three and six months ended June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.69%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
conferences earnings
-
Rhea-AI Summary
PolyPid announces potent antibacterial activity of D-PLEX100 in surgical site infections
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
none
Polypid Ltd

Nasdaq:PYPD

PYPD Rankings

PYPD Stock Data

22.55M
1.69M
30.08%
39.71%
0.09%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Israel
Petah Tikva

About PYPD

polypid®, a specialty pharmaceutical company, develops and manufactures products based on its plex™ technology. so far, 70 patients have been treated in clinical trials with polypid’s anti-infection products demonstrating safety and efficacy. polypid is in the process of submitting its lead product for phase-iii trial in the us and eu. plex™ is able to optimize drugs'​ therapeutic performance and clinical outcomes. plex™-based protected drug reservoir is implanted directly into the body’s target area thus enabling prolonged delivery of drugs, over periods ranging from days to several months. polypid’s pipeline focuses on 3 products: d-plex™ - intended for prevention and treatment of surgical infections caused by bacteria. its effectiveness is currently being tested in patients undergoing open-heart surgery, with a view to preventing infections that may occur following surgery. the product is currently undergoing clinical studies at several medical centers. bonypid®-1000 - designed to e